- Home
- BDX
as 03-25-2025 1:30pm EST
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
| Founded: | 1897 | Country: | United States |
| Employees: | N/A | City: | FRANKLIN LAKES |
| Market Cap: | 64.9B | IPO Year: | 1962 |
| Target Price: | $278.29 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 5.94 | EPS Growth: | 41.25 |
| 52 Week Low/High: | $218.75 - $251.99 | Next Earning Date: | 05-01-2025 |
| Revenue: | $20,640,000,000 | Revenue Growth: | 5.89% |
| Revenue Growth (this year): | 9.21% | Revenue Growth (next year): | 4.97% |
Stock Insider Trading Activity of Becton Dickinson and Company (BDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Byrd Richard | BDX | EVP & President Interventional | Mar 18 '25 | Sell | $230.00 | 459 | $105,570.00 | 6,952 | |
| Byrd Richard | BDX | EVP & President Interventional | Mar 12 '25 | Sell | $224.91 | 1,940 | $436,325.40 | 6,952 | |
| SCOTT BERTRAM L | BDX | Director | Feb 12 '25 | Sell | $227.99 | 700 | $159,593.00 | 36,033 | |
| Henderson Jeffrey William | BDX | Director | Feb 10 '25 | Buy | $233.62 | 1,500 | $350,430.00 | 8,015 | |
| Neal Shana Carol | BDX | EVP and Chief People Officer | Jan 21 '25 | Sell | $240.00 | 787 | $188,880.00 | 15,414 | |
| Shan David | BDX | EVP and Chief ISC Officer | Jan 21 '25 | Sell | $240.00 | 500 | $120,000.00 | 5,741 | |
| Garrison Michael David | BDX | EVP & President, Medical | Jan 17 '25 | Sell | $236.51 | 597 | $141,196.47 | 5,544 |
Latest Becton Dickinson and Company News
BDX Breaking Stock News: Dive into BDX Ticker-Specific Updates for Smart Investing
Zacks
a day ago
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
Insider Monkey
3 days ago
Was Jim Cramer Right About Becton, Dickinson and Company (BDX)?
Medical Device Network
4 days ago
FDA tags Becton, Dickinson and Company infusion software recall as Class I
Medical Device Network
4 days ago
BD treats first subject in trial of bioabsorbable scaffold
Zacks
4 days ago
Why Becton Dickinson (BDX) is a Top Growth Stock for the Long-Term
MT Newswires
5 days ago
Becton, Dickinson Treats First Breast Revision Patient in GalaFlex Lite Scaffold Trial
PR Newswire
5 days ago
BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery
Zacks
6 days ago
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
Compare BDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDX Becton Dickinson and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.